ADMB-3TMS-PRINACA
Nowadays, ADMB-3TMS-PRINACA has become a topic of great importance in today's society. More and more people are interested in learning more about ADMB-3TMS-PRINACA and its implications in different areas of life. From politics to technology to popular culture, ADMB-3TMS-PRINACA has proven to have a significant impact on our lives. In this article we will explore different aspects of ADMB-3TMS-PRINACA, analyzing its origin, evolution and its influence today. Additionally, we will take a closer look at how ADMB-3TMS-PRINACA has shaped and continues to shape the world around us. Join us on this journey of discovery about ADMB-3TMS-PRINACA!
 | |
| Identifiers | |
|---|---|
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C20H32N4O2Si |
| Molar mass | 388.587 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
ADMB-3TMS-PRINACA (ADB-3TMS-PRINACA) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug, first identified in Germany in March 2023. It is the first designer drug ever reported that contains a silicon atom.[1]
Legality
ADMB-3TMS-PRINACA is illegal in Germany and Italy.[2]
See also
References
- ^ "New psychoactive substances - the current situation in Europe" (PDF). European Drug Report. European Union Drugs Agency (EUDA). 2024.
- ^ "Notizie dalla FNOMCeO" [News from FNOMCeO]. Order of Surgeons and Dentists of the province of Brescia (in Italian).
Update of the tables containing the indication of narcotic and psychotropic substances. Inclusion in Table I of the specific indication of the substances: 2'-fluoro-2-fluoro-3-methylfentanyl; N-cyclohexyl butylone; ADMB-3TMSPrinaca
 | This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |